Zygel's anticipated impact on underserved fragile X syndrome market

23 March 2022

Transdermal cannabinoid specialist Zynerba Pharmaceuticals’ (Nasdaq: ZYNE) pipeline drug Zygel is expected to achieve $18.1 million in sales by 2030, according to GlobalData, due to its potential to help fragile X syndrome (FXS) patients with irritability or aggression symptoms.

The data and analytics company notes that Zygel is one of four novel pipeline products set to make a huge impact on the treatment of this underserved genetic condition. Of the four, Zygel is expected to lead the market.

FXS causes a range of developmental problems, including learning disabilities and cognitive impairment. Zygel is a gel applied to the skin that could be beneficial for the population of FXS patients with symptoms of irritability, social avoidance, hyperactivity, and inappropriate speech. It is expected to launch in the USA and Germany in 2025 and 2026, respectively.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK